COMPREHENSIVE CANCER INFRASTRUCTURES 4 EUROPE

Akronym

CCI4EU

Bidragets beskrivning

"Cancer is the second leading cause of death in Europe with an expected increase of about 25% by 2035. A wide and unacceptable variability in terms of access to research, innovation and quality care exists between and within countries. Possible solutions are an increase in knowledge by funding research, and a more equitable transfer of what we already know to everyone. Comprehensive Cancer Centers and Comprehensive Cancer Care Networks may be the core of CCIs that deliver quality care and provide resources to improve and integrate care, research and education. Data already available confirm that the level of ""CCI maturity"" in Member States is widely different, from some countries lacking CCIs completely. A European initiative, implemented in all Member States, based on a capacity building programme (CBP), will help reduce inequalities, in the context of other actions ongoing, such as CRANE, JANE and UNCAN. CBP is a complex intervention that requires multiple and integrated actions delivered to all the relevant stakeholders. CBP will be designed with an inclusive approach, tailored to the baseline status, capable of creating a change and improvement in research and care, with greater integration between them, supported by an education programme. It will operate at various levels: Individuals, Institutions and Systems. The CSA will implement the following steps: define CCI Maturity Model including quality indicators; profile the CCIs in each MS and a few ACs in terms of CCI presence and levels of maturity; design tailored CBP interventions, giving priority to MSs without any CCI; deliver online training courses open to teams in all MSs and ACs, implement targeted onsite interventions; scale up and sustain development; disseminate, exploit and report results. The CSA will maximize impact by bridging with the work of ongoing EU cancer research projects. National focal points will be key informants in making the links between the CSA, the EC and MSs."
Visa mer

Startår

2023

Slutår

2026

Beviljade finansiering

SAVMESTNA ONKOLOGICHNA NATSIONALNA MREZHA (BG)
16 750 €
Third party
SCUOLA EUROPEA DI ONCOLOGIA ASSOCIAZIONE (IT)
329 500 €
Participant
INSTITUT NATIONAL DU CANCER (LU)
50 916.25 €
Third party
DIGITAL INSTITUTE FOR CANCER OUTCOMES RESEARCH (BE)
131 875 €
Participant
GENIKO ANTIKARKINIKO OGKOLOGIKO NOSOKOMEIO ATHINON O AGIOS SAVVAS (EL)
57 375 €
Third party
SCIENSANO (BE)
490 090 €
Participant
G.O.C.GERMAN ONCOLOGY CENTER LIMITED (CY)
16 875 €
Third party
NACIONALINIS VEZIO INSTITUTAS (LT)
14 250 €
Third party
FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS (IT)
101 875 €
Third party
BIOMEDICINSKE CENTRUM SLOVENSKEJ AKADEMIE VIED (SK)
8 212.5 €
Third party
DEUTSCHE KREBSGESELLSCHAFT EV (DE)
344 875 €
Participant
STICHTING INTEGRAAL KANKERCENTRUM NEDERLAND (NL)
391 750 €
Participant
UNICANCER (FR)
233 582.5 €
Participant
FONDAZIONE DEL PIEMONTE PER L'ONCOLOGIA (IT)
28 625 €
Third party
INSTITUTIA MEDICO-SANITARA PUBLICA INSTITUTUL ONCOLOGIC (MD)
8 750 €
Third party
KLINICKI BOLNICKI CENTAR SESTRE MILOSRDNICE USTANOVA (HR)
8 751.25 €
Third party
Ministry for Health - Government of Malta (MT)
15 625 €
Participant
ISTITUTI FISIOTERAPICI OSPITALIERI (IT)
157 375 €
Third party
MASARYKUV ONKOLOGICKY USTAV (CZ)
131 875 €
Participant
ONKOLOSKI INSTITUT LJUBLJANA (SI)
57 375 €
Third party
R.E KAVETSKY INSTITUTE OF EXPERIMENTAL PATHOLOGY, ONCOLOGY AND RADIOBIOLOGY OF NATIONAL ACADEMY OF SCIENCES OF UKRAINE (UA)
12 500 €
Third party
INSTITUTUL ONCOLOGIC PROF DR ION CHIRICUTA CLUJ-NAPOCA (RO)
27 750 €
Third party
OSLO UNIVERSITETSSYKEHUS HF (NO)
314 345 €
Participant
INSTITUT JULES BORDET (BE)
71 125 €
Third party
Orszagos Onkologiai Intezet (HU)
126 437.5 €
Participant
FUNDACIO PRIVADA INSTITUT D'INVESTIGACIO ONCOLOGICA DE VALL-HEBRON (ES)
352 090 €
Participant
INSTITUTO PORTUGUES DE ONCOLOGIA DO PORTO FRANCISCO GENTIL, EPE (PT)
70 750 €
Third party
ORGANISATION OF EUROPEAN CANCER INSTITUTES (BE)
2 576 875 €
Coordinator
EUROPEAN CANCER ORGANISATION (BE)
97 875 €
Participant
SKANE LANS LANDSTING (SE)
57 250 €
Third party
LUXEMBOURG INSTITUTE OF HEALTH (LU)
98 166.25 €
Participant
NARODOWY INSTYTUT ZDROWIA PUBLICZNEGO-PANSTWOWY ZAKLAD HIGIENY (PL)
121 265 €
Participant
INSTITUT CATALA D'ONCOLOGIA (ES)
71 475 €
Third party
FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI (IT)
351 875 €
Participant
INSTITUT GUSTAVE ROUSSY (FR)
371 812.5 €
Participant
SIHTASUTUS TARTU ULIKOOLI KLIINIKUM (EE)
71 750 €
Third party
CENTRE INTERNATIONAL DE RECHERCHE SUR LE CANCER (FR)
348 581.25 €
Participant
STOCKHOLMS LANS LANDSTING (SE)
159 227.5 €
Third party
EUROPEAN ORGANISATION FOR RESEARCH AND TREATMENT OF CANCER AISBL (BE)
165 500 €
Participant
NARODOWY INSTYTUT ONKOLOGII IM. MARII SKLODOWSKIEJ-CURIE -PANSTWOWY INSTYTUT BADAWCZY (PL)
126 595 €
Participant
ALLEANZA CONTRO IL CANCRO (IT)
206 875 €
Participant
ACADEMISCH ZIEKENHUIS MAASTRICHT (NL)
32 375 €
Third party
REGION SYDDANMARK (DK)
44 125 €
Third party
THE PROVOST, FELLOWS, FOUNDATION SCHOLARS & THE OTHER MEMBERS OF BOARD OF THE COLLEGE OF THE HOLY & UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLIN (IE)
186 185 €
Third party
LATVIJAS UNIVERSITATE (LV)
53 375 €
Participant
INSTITUT CURIE (FR)
150 376.25 €
Participant
TECHNISCHE UNIVERSITAET DRESDEN (DE)
354 437.5 €
Participant
KAROLINSKA INSTITUTET (SE)
146 687.5 €
Participant
JOHANN WOLFGANG GOETHE-UNIVERSITATFRANKFURT AM MAIN (DE)
71 625 €
Third party
STICHTING HET NEDERLANDS KANKER INSTITUUT-ANTONI VAN LEEUWENHOEK ZIEKENHUIS (NL)
145 625 €
Third party
MEDIZINISCHE UNIVERSITAET WIEN (AT)
16 750 €
Third party
DEUTSCHES KREBSFORSCHUNGSZENTRUM HEIDELBERG (DE)
155 596.25 €
Participant

Beviljat belopp

9 984 080 €

Finansiär

Europeiska unionen

Typ av finansiering

HORIZON Coordination and Support Actions

Ramprogram

Horizon Europe (HORIZON)

Utlysning

Programdel
Health (11673)
Tema
Strengthening research capacities of Comprehensive Cancer Infrastructures (HORIZON-MISS-2022-CANCER-01-02)
Utlysnings ID
HORIZON-MISS-2022-CANCER-01

Övriga uppgifter

Finansieringsbeslutets nummer

101103746